2022
OUTCOMES OF TOTAL PROCTOCOLECTOMY (TPC) WITH ILEAL POUCH ANAL ANASTOMOSIS (IPAA)
Petrov J, Al-Bawardy B, Gaidos J, Proctor D. OUTCOMES OF TOTAL PROCTOCOLECTOMY (TPC) WITH ILEAL POUCH ANAL ANASTOMOSIS (IPAA). Inflammatory Bowel Diseases 2022, 28: s75-s76. DOI: 10.1093/ibd/izac015.123.Peer-Reviewed Original ResearchIleal pouch-anal anastomosisPouch-anal anastomosisTotal proctocolectomyMedical therapyCrohn's diseaseChronic pouchitisRepeat surgeryAnal anastomosisAnatomic complicationsChronic antibiotic-refractory pouchitisAntibiotic-refractory pouchitisBiopsy-proven inflammationChronic steroid therapyEpisodes of pouchitisPre-pouch ileitisSymptoms of pouchitisAdverse postoperative outcomesRate of complicationsSurgery of choiceUlcerative colitis patientsTreatment of complicationsMulti-center studyThird of subjectsAcute pouchitisAnatomical complicationsIMPACT OF THIOPURINE DOSE IN COMBINATION THERAPY IN INFLAMMATORY BOWEL DISEASE
Nawaz A, Glick L, Li D, Gaidos J, Proctor D, Al-Bawardy B. IMPACT OF THIOPURINE DOSE IN COMBINATION THERAPY IN INFLAMMATORY BOWEL DISEASE. Inflammatory Bowel Diseases 2022, 28: s107-s108. DOI: 10.1093/ibd/izac015.174.Peer-Reviewed Original ResearchSteroid-free clinical remissionC-reactive proteinNon-therapeutic dosesInflammatory bowel diseaseNormal C-reactive proteinAnti-TNF antibodiesCombination therapyTherapeutic doseEndoscopic healingNTD groupAntibody formationUlcerative colitisClinical outcomesCrohn's diseaseNormal serum C-reactive proteinAnti-TNF combination therapyAnti-TNF drug levelsSerum C-reactive proteinEffect of thiopurinesImpact of thiopurinesAnti-TNF treatmentRetrospective cohort studyNormal TPMT activityUnpaired Student's t-testTerms of baselineImpact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease
Nawaz A, Glick L, Chaar A, Li D, Gaidos J, Proctor D, Al-Bawardy B. Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease. Annals Of Gastroenterology 2022, 36: 39-44. PMID: 36593807, PMCID: PMC9756033, DOI: 10.20524/aog.2022.0766.Peer-Reviewed Original ResearchInflammatory bowel diseaseC-reactive proteinAnti-TNF combination therapySteroid-free clinical remissionCombination therapyThiopurine doseDose groupEndoscopic healingClinical remissionBowel diseaseUlcerative colitisCrohn's diseaseTherapeutic doseNormal serum C-reactive proteinAnti-tumor necrosis factorNormal C-reactive proteinSerum C-reactive proteinAnti-drug antibody formationAnti-TNF immunogenicityCohort of patientsLow-dose groupSignificant differencesSecondary outcomesPrimary outcomeClinical outcomes
2021
Novel and Emerging Therapies for Inflammatory Bowel Disease
Al-Bawardy B, Shivashankar R, Proctor DD. Novel and Emerging Therapies for Inflammatory Bowel Disease. Frontiers In Pharmacology 2021, 12: 651415. PMID: 33935763, PMCID: PMC8080036, DOI: 10.3389/fphar.2021.651415.BooksInflammatory bowel diseaseBowel diseaseAnti-tumor necrosis factorPotential systemic manifestationsSecondary treatment failureTreatment response ratesJanus kinase inhibitorSelective Janus kinase inhibitorNew therapeutic targetsEmerging TherapiesCurrent biologicsIntestinal inflammationSystemic manifestationsUlcerative colitisCrohn's diseaseTreatment failureSafety profileNecrosis factorTherapeutic targetResponse rateDiseaseKinase inhibitorsTarget agentsInhibitorsTolerability
2019
0636 Activity-Rest Patterns and Symptoms in Inflammatory Bowel Disease
Conley S, Jeon S, Lehner V, Proctor D, Redeker N. 0636 Activity-Rest Patterns and Symptoms in Inflammatory Bowel Disease. Sleep 2019, 42: a253-a253. DOI: 10.1093/sleep/zsz067.634.Peer-Reviewed Original ResearchInflammatory bowel diseaseSymptom groupsLow symptom groupActivity-rest patternBedtime melatoninBowel diseaseCo-occurring painSymptoms of fatigueVisual analog scaleBright light therapyLower interdaily stabilityActive diseaseSymptom burdenPROMIS scalesCrohn's diseaseAnalog scaleSleep disturbancesUnpredictable courseActivity-rest rhythmsChronic diseasesAdults 18RemissionLight therapyWrist actigraphySalivary melatonin
2017
Knowledge Gaps in the Management of Postoperative Crohn’s Disease: A US National Survey
Nguyen VQ, Mays JL, Lang M, Wu Y, Dassopoulos T, Regueiro M, Moss A, Proctor DD, Sorrentino D. Knowledge Gaps in the Management of Postoperative Crohn’s Disease: A US National Survey. Digestive Diseases And Sciences 2017, 63: 53-60. PMID: 29147878, DOI: 10.1007/s10620-017-4844-z.Peer-Reviewed Original ResearchConceptsMedical prophylaxisCrohn's diseaseEndoscopic findingsClinical practicePostoperative Crohn's diseasePrior intestinal surgerySubsequent endoscopic findingsHigh-risk patientsEndoscopic scoring systemEarly disease onsetHigh-risk factorsAmerican Gastroenterological AssociationCurrent clinical practiceCombination of symptomsBackgroundPostoperative recurrenceUS National SurveyEndoscopic recurrenceCD patientsClinical recurrenceIntestinal surgeryMajority of participantsPerianal fistulasResultsA totalDisease onsetPatient riskSymptom clusters in adults with inflammatory bowel disease
Conley S, Proctor DD, Jeon S, Sandler RS, Redeker NS. Symptom clusters in adults with inflammatory bowel disease. Research In Nursing & Health 2017, 40: 424-434. PMID: 28833284, PMCID: PMC5597486, DOI: 10.1002/nur.21813.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseSymptom burdenBowel diseaseHigh symptom burden groupSymptom clustersOutcomes Measurement Information System (PROMIS) measuresLower symptom burdenHigh symptom burdenActive disease stateLatent class analysisSymptom management interventionsSymptom cluster groupsSymptom cluster membershipClinical factorsCrohn's diseasePain interferenceBurden groupRetrospective studyColitis FoundationSleep disturbancesFemale genderReduced qualityPhysical symptomsPsychological symptomsSymptoms
2016
A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn’s Disease and Human Gut Microbiome Composition
Li D, Achkar JP, Haritunians T, Jacobs JP, Hui KY, D'Amato M, Brand S, Radford-Smith G, Halfvarson J, Niess JH, Kugathasan S, Büning C, Schumm LP, Klei L, Ananthakrishnan A, Aumais G, Baidoo L, Dubinsky M, Fiocchi C, Glas J, Milgrom R, Proctor DD, Regueiro M, Simms LA, Stempak JM, Targan SR, Törkvist L, Sharma Y, Devlin B, Borneman J, Hakonarson H, Xavier RJ, Daly M, Brant SR, Rioux JD, Silverberg MS, Cho JH, Braun J, McGovern DP, Duerr RH. A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn’s Disease and Human Gut Microbiome Composition. Gastroenterology 2016, 151: 724-732. PMID: 27492617, PMCID: PMC5037008, DOI: 10.1053/j.gastro.2016.06.051.Peer-Reviewed Original ResearchConceptsCrohn's diseaseMissense variantsMicrobiome compositionGut microbiome compositionInflammatory bowel disease lociCD risk allelesIBD controlsCD patientsUlcerative colitisBlood pressureIBD casesSolute carrier family 39Overweight individualsHealthy controlsLavage samplesLipid levelsFunctional genetic variantsCD casesIndependent cohortHuman gut microbiome compositionReplication cohortGut microbiomeAbstractTextRisk allelesDisease
2013
EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging
Faubion WA, Fletcher JG, O'Byrne S, Feagan BG, de Villiers WJ, Salzberg B, Plevy S, Proctor DD, Valentine JF, Higgins PD, Harris JM, Diehl L, Wright L, Tew GW, Luca D, Basu K, Keir ME. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging. The American Journal Of Gastroenterology 2013, 108: 1891. PMID: 24126633, DOI: 10.1038/ajg.2013.354.Peer-Reviewed Original ResearchConceptsComputed tomography enterographySerum IL-22Disease activityFecal calprotectinCrohn's diseaseSerum MMP9Ulcerative colitisCross-sectional imagingCD patientsIL-22Serum matrix metalloproteinase-9Bowel wall inflammationInflammatory disease activitySerum interleukin‐22Inflammatory bowel diseaseFindings of inflammationCrohn's disease activityMatrix metalloproteinase-9Endoscopy subscoreTomography enterographyUC patientsEndoscopy scoresBowel diseaseClinical symptomsWall inflammationThe Influence of Depression on Quality of Life in Patients with Inflammatory Bowel Disease
Zhang CK, Hewett J, Hemming J, Grant T, Zhao H, Abraham C, Oikonomou I, Kanakia M, Cho JH, Proctor DD. The Influence of Depression on Quality of Life in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2013, 19: 1732-1739. PMID: 23669400, PMCID: PMC4623582, DOI: 10.1097/mib.0b013e318281f395.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseDisease activity indexHR-QOLCrohn's diseaseUlcerative colitisDisease activityBowel diseaseQuality of lifeActivity indexShort Inflammatory Bowel Disease QuestionnaireDepression InventoryInflammatory bowel disease practiceCrohn's Disease Activity IndexInflammatory Bowel Disease QuestionnairePatients' HR-QOLSeo activity indexBowel Disease QuestionnaireHealth-related qualityPoorer HR-QOLChronic inflammatory disordersPrevalence of depressionBeck Depression Inventory-IIDiagnosis of depressionCross-sectional studyImportance of depressionMo1241 Patterns of Extraintestinal Manifestations in Ulcerative Colitis and Crohn's Disease: Results From a Large Cross-Sectional Cohort
Koh J, Limketkai B, Parian A, Brant S, Bitton A, Cho J, Duerr R, McGovern D, Proctor D, Regueiro M, Rioux J, Schumm L, Taylor K, Silverberg M, Steinhart A, Lazarev M. Mo1241 Patterns of Extraintestinal Manifestations in Ulcerative Colitis and Crohn's Disease: Results From a Large Cross-Sectional Cohort. Gastroenterology 2013, 144: s-615. DOI: 10.1016/s0016-5085(13)62274-x.Peer-Reviewed Original Research
2010
760 Divergence in L4 Crohn's Disease: Jejunal, Not Esophagogastroduodenal Involvement, is Protective of L2 Disease Location, and a Risk for Stricturing Behavior and Multiple Abdominal Surgeries. Report From the NIDDK-IBDGC Registry
Lazarev M, Hutfless S, Bitton A, Cho J, Duerr R, McGovern D, Proctor D, Regueiro M, Rioux J, Schumm P, Taylor K, Silverberg M, Steinhart H, Brant S. 760 Divergence in L4 Crohn's Disease: Jejunal, Not Esophagogastroduodenal Involvement, is Protective of L2 Disease Location, and a Risk for Stricturing Behavior and Multiple Abdominal Surgeries. Report From the NIDDK-IBDGC Registry. Gastroenterology 2010, 138: s-105. DOI: 10.1016/s0016-5085(10)60481-7.Peer-Reviewed Original Research
2009
Phenotypic and Genotypic Characteristics of Inflammatory Bowel Disease in French Canadians: Comparison With a Large North American Repository
Elkadri A, Bitton A, Cohen A, Griffiths A, Deslandres C, Proctor D, McGovern D, Langelier D, Bernard E, Torres E, Wild G, Nguyen G, Jobin G, Aumais G, Steinhart H, Rioux J, Cho J, Bhat M, Silverberg M, Regueiro M, Goyette P, Pare P, Lahaie R, Duerr R, Brant S, Dassopoulos T. Phenotypic and Genotypic Characteristics of Inflammatory Bowel Disease in French Canadians: Comparison With a Large North American Repository. The American Journal Of Gastroenterology 2009, 104: 2233. PMID: 19513023, PMCID: PMC2742627, DOI: 10.1038/ajg.2009.267.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseCrohn's diseaseBowel diseaseUlcerative colitisSingle nucleotide polymorphismsManagement of IBDCaucasian IBD populationsSmall bowel diseaseFrench-Canadian patientsExtraintestinal manifestationsCurrent smokersFormer smokersIBD phenotypeIBD populationCD patientsSmoking statusIncreased prevalenceKidney diseaseSurgical historyCaucasian patientsDisease behaviorFamily historyPatientsAnatomical locationDisease